Thymosin Alpha-1

Thymosin alpha-1, generic name thymalfasin, is a chain of 28 amino acids with an acetyl cap on one end. Unlike the extracts elsewhere in this reference it is a molecule you can draw: the regulator's chemistry review prints the whole sequence and a molecular weight of 3,108.3, so a laboratory report has something definite to check a vial against. It has a real marketing authorisation behind it, in Italy, and real randomised trials. Those two things are not about the same disease, and that gap is the whole entry.

It was first isolated in 1977 from thymosin fraction 5, a partly purified calf thymus extract that the researcher who named it described as a family of at least 40 mostly small acidic polypeptides. The selling premise is that the thymus, the gland that trains immune cells, shrinks with age, so its hormone falls, so replacing it restores immunity. Two things in the published record cut against that premise rather than for it. Serum thymosin alpha-1 measured in 681 healthy adults aged 18 to 101 showed no differences by race, sex or age. And the two researchers who built the vaccine adjuvant case opened their own review by writing that the immune deficiency of ageing is not profound and may be of little clinical consequence, before adding that older people with chronic illness and the medications that go with it are a different matter. They are not undercutting themselves. They are saying that a birthday on its own is not the problem, which is a problem for anybody selling this to a healthy person.

Immune support in healthy adults, infection resistance and longevity generally. What is actually registered is one thing: section 4.1 of the Italian label is a single sentence naming it an adjuvant to influenza vaccination in immunocompromised subjects, meaning something given alongside the shot to make the shot work better in people whose immune systems are already damaged. Not hepatitis, which is what the sales copy cites. Not immune support. The American regulator reviewed five studies of exactly that registered use in December 2024 and found a lack of sufficient evidence to reach any conclusion on it.

The costly mistake is reading one document as though it licensed the other. A real registration exists and a real trial literature exists, and vendor pages weld them together. The registration is Italian and covers flu vaccination in immunocompromised patients. The trials are sepsis and hepatitis, and the two largest placebo controlled ones came back null: 28 day deaths of 23.4 percent against 24.1 in 1,106 septic adults, and hepatitis C cure rates of 12.7 against 10.5 percent in 552 patients. Read the corrected version of that sepsis paper, too, because the journal corrected it in place in May 2025 and the PubMed abstract still prints the old hazard ratio. Every piece of this is real. The picture assembled out of them is not.

Start with what is reassuring, because it is. The regulator concluded that in most clinical studies the peptide has not been associated with significant adverse events attributable to it, at 1 to 16 mg under the skin for up to twelve months, with irritation where the needle went in the commonest complaint, and the sepsis trial found adverse events in 66.4 percent of the 542 patients on the drug against 67.6 percent of the 547 on placebo. The specific harms are about who takes it. The regulator warns that stimulating immunity in someone whose immunity is being deliberately suppressed could cause or worsen graft versus host disease and lead to engraftment failure, and in one transplant study six patients had a half matched donor, of whom five were alive and disease free at a median of 10 months while one developed fatal immune haemolytic anaemia, in which the immune system destroys the person's own red blood cells. The Italian label rules the product out in pregnancy, breastfeeding and children, and says autoimmune disease must be assessed case by case. Then the subgroup, which is the sharpest thing in the file: in the largest blinded trial, in a split planned before anyone saw the results, patients under 60 had a hazard of death of 1.67 against 0.81 in those aged 60 and over.